Science 6 September 1985: Vol. 229. no. 4717, pp. 974 - 976 DOI: 10.1126/science.2992089

Prev | Table of Contents | Next

Articles

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, et al. (2009)
PNAS 106, 10284-10289
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 as a Target for Breast Cancer Therapy.

M. Ignatiadis, C. Desmedt, C. Sotiriou, E. de Azambuja, and M. Piccart (2009)
Clin. Cancer Res. 15, 1848-1852
 |  Full Text »  |  PDF »

Association between frequent CpG island methylation and HER2 amplification in human breast cancers.

K. Terada, E. Okochi-Takada, S. Akashi-Tanaka, K. Miyamoto, K. Taniyama, H. Tsuda, K. Asada, M. Kaminishi, and T. Ushijima (2009)
Carcinogenesis 30, 466-471
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors.

M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi (2009)
Clin. Cancer Res. 15, 924-932
 |  Abstract »  |  Full Text »  |  PDF »

Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPAR{beta}/{delta} to RAR.

T. T. Schug, D. C. Berry, I. A. Toshkov, L. Cheng, A. Y. Nikitin, and N. Noy (2008)
PNAS 105, 7546-7551
 |  Abstract »  |  Full Text »  |  PDF »

Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells.

C.-C. Ou, S.-C. Hsu, Y.-H. Hsieh, W.-L. Tsou, T.-C. Chuang, J.-Y. Liu, and M.-C. Kao (2008)
Carcinogenesis 29, 299-306
 |  Abstract »  |  Full Text »  |  PDF »

Oncogenes and Cancer.

C. M. Croce (2008)
N. Engl. J. Med. 358, 502-511
 |  Full Text »  |  PDF »

An EGR2/CITED1 Transcription Factor Complex and the 14-3-3{sigma} Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer.

R. L. Dillon, S. T. Brown, C. Ling, T. Shioda, and W. J. Muller (2007)
Mol. Cell. Biol. 27, 8648-8657
 |  Abstract »  |  Full Text »  |  PDF »

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr (2007)
J. Clin. Oncol. 25, 5287-5312
 |  Abstract »  |  Full Text »  |  PDF »

Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu.

M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo (2007)
Cancer Res. 67, 6825-6843
 |  Abstract »  |  Full Text »  |  PDF »

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial.

B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al. (2007)
J. Clin. Oncol. 25, 2678-2684
 |  Abstract »  |  Full Text »  |  PDF »

Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk.

K. Einarsdottir, K. Humphreys, C. Bonnard, Y. Li, Y. Li, K. S. Chia, E. T. Liu, P. Hall, J. Liu, and S. Wedren (2007)
Hum. Mol. Genet. 16, 154-164
 |  Abstract »  |  Full Text »  |  PDF »

HER2 Inhibition: From Discovery to Clinical Practice.

J. C. Chang (2007)
Clin. Cancer Res. 13, 1-3
 |  Full Text »  |  PDF »

Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer.

Z. Gabos, R. Sinha, J. Hanson, N. Chauhan, J. Hugh, J. R. Mackey, and B. Abdulkarim (2006)
J. Clin. Oncol. 24, 5658-5663
 |  Abstract »  |  Full Text »  |  PDF »

Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells..

P. Garcia-Morales, E. Hernando, E. Carrasco-Garcia, M. P. Menendez-Gutierrez, M. Saceda, and I. Martinez-Lacaci (2006)
Mol. Cancer Ther. 5, 2172-2181
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neu Mouse Model of Breast Cancer..

R. Singh and Y. Paterson (2006)
Cancer Res. 66, 7748-7757
 |  Abstract »  |  Full Text »  |  PDF »

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

B. P. Coudert, L. Arnould, L. Moreau, P. Chollet, B. Weber, L. Vanlemmens, C. Molucon, N. Tubiana, S. Causeret, J.-L. Misset, et al. (2006)
Ann. Onc. 17, 409-414
 |  Abstract »  |  Full Text »  |  PDF »

Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers.

G. P. Adams, M.-S. Tai, J. E. McCartney, J. D. Marks, W. F. Stafford III, L.L. Houston, J. S. Huston, and L. M. Weiner (2006)
Clin. Cancer Res. 12, 1599-1605
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer..

M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. (2005)
N. Engl. J. Med. 353, 1659-1672
 |  Abstract »  |  Full Text »  |  PDF »

Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse.

R. Singh, M. E. Dominiecki, E. M. Jaffee, and Y. Paterson (2005)
J. Immunol. 175, 3663-3673
 |  Abstract »  |  Full Text »  |  PDF »

Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials.

M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al. (2005)
Clin. Cancer Res. 11, 6598-6607
 |  Abstract »  |  Full Text »  |  PDF »

ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty.

R. J. Gilbertson (2005)
Oncologist 10, 508-517
 |  Abstract »  |  Full Text »  |  PDF »

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

J. Norum, T. Risberg, and J. A. Olsen (2005)
Ann. Onc. 16, 909-914
 |  Abstract »  |  Full Text »  |  PDF »

The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.

B. Frank, K. Hemminki, M. Wirtenberger, J. L. Bermejo, P. Bugert, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, C. R. Bartram, and B. Burwinkel (2005)
Carcinogenesis 26, 643-647
 |  Abstract »  |  Full Text »  |  PDF »

Putting the Rap on Akt.

J. E. Thompson and C. B. Thompson (2004)
J. Clin. Oncol. 22, 4217-4226
 |  Abstract »  |  Full Text »  |  PDF »

Genomic DNA-Chip Hybridization Reveals a Higher Incidence of Genomic Amplifications in Pancreatic Cancer than Conventional Comparative Genomic Hybridization and Leads to the Identification of Novel Candidate Genes.

K. Holzmann, H. Kohlhammer, C. Schwaenen, S. Wessendorf, H. A. Kestler, A. Schwoerer, B. Rau, B. Radlwimmer, H. Dohner, P. Lichter, et al. (2004)
Cancer Res. 64, 4428-4433
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells.

F. Leone, E. Perissinotto, G. Cavalloni, V. Fonsato, S. Bruno, N. Surrenti, D. Hong, A. Capaldi, M. Geuna, W. Piacibello, et al. (2003)
J. Leukoc. Biol. 74, 593-601
 |  Abstract »  |  Full Text »  |  PDF »

Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II.

D. Manor, E. N. Shmidt, A. Budhu, A. Flesken-Nikitin, M. Zgola, R. Page, A. Yu. Nikitin, and N. Noy (2003)
Cancer Res. 63, 4426-4433
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Studies of Vaccines Targeting Breast Cancer.

B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides (2003)
Clin. Cancer Res. 9, 3222-3234
 |  Abstract »  |  Full Text »  |  PDF »

Lanthionine Synthetase Components C-like 2 Increases Cellular Sensitivity to Adriamycin by Decreasing the Expression of P-Glycoprotein through a Transcription-mediated Mechanism.

S. Park and C. D. James (2003)
Cancer Res. 63, 723-727
 |  Abstract »  |  Full Text »  |  PDF »

Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention.

R. Nahta, G. N. Hortobagyi, and F. J. Esteva (2003)
Oncologist 8, 5-17
 |  Abstract »  |  Full Text »  |  PDF »

c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma.

J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta (2002)
International Journal of Surgical Pathology 10, 247-256
 |  Abstract »  |  PDF »

Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer.

S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton (2002)
Clin. Chem. 48, 1314-1320
 |  Abstract »  |  Full Text »  |  PDF »

A New Human Antitumor Immunoreagent Specific for ErbB2.

C. De Lorenzo, D. B. Palmer, R. Piccoli, M. A. Ritter, and G. D'Alessio (2002)
Clin. Cancer Res. 8, 1710-1719
 |  Abstract »  |  Full Text »  |  PDF »

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer.

F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al. (2002)
J. Clin. Oncol. 20, 1800-1808
 |  Abstract »  |  Full Text »  |  PDF »

A new mutator phenotype in breast cancer?.

J. G. de Boer (2002)
PNAS 99, 3368-3369
 |  Full Text »  |  PDF »

Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer.

A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H. A. Harvey, C. Brady, C.M. Nalin, M. Dugan, et al. (2002)
J. Clin. Oncol. 20, 1467-1472
 |  Abstract »  |  Full Text »  |  PDF »

A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody.

M. Ohta, Y. Tokuda, Y. Suzuki, M. Kubota, T. Watanabe, H. Fujii, Y. Sasaki, T. Niwa, H. Makuuchi, and T. Tajima (2001)
Jpn. J. Clin. Oncol. 31, 553-556
 |  Abstract »  |  Full Text »  |  PDF »

Her-2/neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors.

R. E. Jimenez, M. Hussain, F. J. Bianco Jr., U. Vaishampayan, P. Tabazcka, W. A. Sakr, J. E. Pontes, D. P. Wood Jr., and D. J. Grignon (2001)
Clin. Cancer Res. 7, 2440-2447
 |  Abstract »  |  Full Text »  |  PDF »

When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer.

H. Yamauchi, V. Stearns, and D. F. Hayes (2001)
J. Clin. Oncol. 19, 2334-2356
 |  Abstract »  |  Full Text »  |  PDF »

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.

D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. (2001)
N. Engl. J. Med. 344, 783-792
 |  Abstract »  |  Full Text »  |  PDF »

Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression.

E. M. Rego, Z.-G. Wang, D. Peruzzi, L.-Z. He, C. Cordon-Cardo, and P. P. Pandolfi (2001)
J. Exp. Med. 193, 521-530
 |  Abstract »  |  Full Text »  |  PDF »

Segment-Specific c-ErbB2 Expression in Human Autosomal Recessive Polycystic Kidney Disease.

K. NAKANISHI, W. E. SWEENEY JR., and E. D. AVNER (2001)
J. Am. Soc. Nephrol. 12, 379-384
 |  Abstract »  |  Full Text »

Prognostic Value of the Type I Growth Factor Receptors in a Large Series of Human Primary Breast Cancers Quantified with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay.

V. Pawlowski, F. Revillion, M. Hebbar, L. Hornez, and J.-P. Peyrat (2000)
Clin. Cancer Res. 6, 4217-4225
 |  Abstract »  |  Full Text »  |  PDF »

Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk.

D. Xie, X.-O. Shu, Z. Deng, W.-Q. Wen, K. E. Creek, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng (2000)
J Natl Cancer Inst 92, 412-417
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter.

T.-C. Suen and P. E. Goss (2000)
J. Biol. Chem. 275, 6600-6607
 |  Abstract »  |  Full Text »  |  PDF »

Pharmacokinetics and Antitumor Activity of a Bivalent Disulfide-stabilized Fv Immunotoxin with Improved Antigen Binding to erbB2.

T. K. Bera, J. Viner, E. Brinkmann, and I. Pastan (1999)
Cancer Res. 59, 4018-4022
 |  Abstract »  |  Full Text »  |  PDF »

Relationship between Protease Activity and neu Oncogene Expression in Patients with Oral Leukoplakia Treated with the Bowman Birk Inhibitor.

X. S. Wan, F. L. Meyskens Jr., W. B. Armstrong, T. H. Taylor, and A. R. Kennedy (1999)
Cancer Epidemiol. Biomarkers Prev. 8, 601-608
 |  Abstract »  |  Full Text »

Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer.

A. T. Baron, J. M. Lafky, C. H. Boardman, S. Balasubramaniam, V. J. Suman, K. C. Podratz, and N. J. Maihle (1999)
Cancer Epidemiol. Biomarkers Prev. 8, 129-137
 |  Abstract »  |  Full Text »

Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo. IMPLICATIONS FOR HUMAN BREAST CANCER.

J. A. Engelman, R. J. Lee, A. Karnezis, D. J. Bearss, M. Webster, P. Siegel, W. J. Muller, J. J. Windle, R. G. Pestell, and M. P. Lisanti (1998)
J. Biol. Chem. 273, 20448-20455
 |  Abstract »  |  Full Text »  |  PDF »

Expression of Q227L-Galpha s in MCF-7 human breast cancer cells inhibits tumorigenesis.

J. Chen, J. A. Bander, T. A. Santore, Y. Chen, P. T. Ram, M. J. Smit, and R. Iyengar (1998)
PNAS 95, 2648-2652
 |  Abstract »  |  Full Text »  |  PDF »

Cross-talk between Phorbol Ester-mediated Signaling and Tyrosine Kinase Proto-oncogenes. I. ACTIVATION OF PROTEIN KINASE C STIMULATES TYROSINE PHOSPHORYLATION AND ACTIVATION OF ErbB2 AND ErbB3.

R. Emkey and C. R. Kahn (1997)
J. Biol. Chem. 272, 31172-31181
 |  Abstract »  |  Full Text »  |  PDF »

The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells.

B. D. Cohen, P. A. Kiener, J. M. Green, L. Foy, H. P. Fell, and K. Zhang (1996)
J. Biol. Chem. 271, 30897-30903
 |  Abstract »  |  Full Text »  |  PDF »

c-erbB-2/p185-Directed Therapy in Human Lung Adenocarcinoma.

J. M. Snider, L. J. Bushnell, L. C. Chen, and L. A. Lanza (1996)
Ann. Thorac. Surg. 62, 1454-1459
 |  Abstract »  |  Full Text »

Induction of Acetylcholine Receptor Gene Expression by ARIA Requires Activation of Mitogen-activated Protein Kinase.

J. Si, Z. Luo, and L. Mei (1996)
J. Biol. Chem. 271, 19752-19759
 |  Abstract »  |  Full Text »  |  PDF »

Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-kappaB-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation.

C. K. Galang, J. J. García-Ramírez, P. A. Solski, J. K. Westwick, C. J. Der, N. N. Neznanov, R. G. Oshima, and C. A. Hauser (1996)
J. Biol. Chem. 271, 7992-7998
 |  Abstract »  |  Full Text »  |  PDF »

A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells.

V De Corte, C De Potter, D Vandenberghe, N Van Laerebeke, M Azam, H Roels, M Mareel, and J Vandekerckhove (1994)
J. Cell Sci. 107, 405-416
 |  Abstract »  |  PDF »

Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice..

C T Guy, S K Muthuswamy, R D Cardiff, P Soriano, and W J Muller (1994)
Genes & Dev. 8, 23-32
 |  Abstract »  |  PDF »

Identification of Heregulin, a Specific Activator of p185erbB2.

W. E. Holmes, M. X. Sliwkowski, R. W. Akita, W. J. Henzel, J. Lee, J. W. Park, D. Yansura, N. Abadi, H. Raab, G. D. Lewis, et al. (1992)
Science 256, 1205-1210
 |  Abstract »  |  PDF »

Growth factors and cancer.

S. Aaronson (1991)
Science 254, 1146-1153
 |  Abstract »  |  PDF »

Oncogene Amplification in Squamous Cell Carcinoma of the Head and Neck.

W. D. Merritt, M. C. Weissler, B. F. Turk, and T. M. Gilmer (1990)
Arch Otolaryngol Head Neck Surg 116, 1394-1398
 |  Abstract »  |  PDF »

Advances in Diagnosis and Detection of Oral Diseases.

B.J. Baum, C.J. Burstone, R. Dubner, P. Goldhaber, M.J. Levine, W.J. Loesche, and V. Terranova (1989)
Advances in Dental Research 3, 7-13
 |  Abstract »  |  PDF »

Amplification of c-erbB-2 and aggressive human breast tumors?.

D. Slamon and G. Clark (1988)
Science 240, 1795-1798
 |  PDF »

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

P. Di Fiore, J. Pierce, M. Kraus, O Segatto, C. King, and S. Aaronson (1987)
Science 237, 178-182
 |  Abstract »  |  PDF »

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

D. Slamon, G. Clark, S. Wong, W. Levin, A Ullrich, and W. McGuire (1987)
Science 235, 177-182
 |  Abstract »  |  PDF »

A novel human gene closely related to the abl proto-oncogene.

G. Kruh, C. King, M. Kraus, N. Popescu, S. Amsbaugh, W. McBride, and S. Aaronson (1986)
Science 234, 1545-1548
 |  Abstract »  |  PDF »

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

T Akiyama, C Sudo, H Ogawara, K Toyoshima, and T Yamamoto (1986)
Science 232, 1644-1646
 |  Abstract »  |  PDF »

The c-erbB-2 Gene Encodes a Receptor-like Protein with Tyrosine Kinase Activity.

K. Toyoshima, K. Semba, T. Akiyama, S. Ikawa, and T. Yamamoto (1986)
Cold Spring Harb Symp Quant Biol 51, 977-982
 |  Abstract »  |  PDF »

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

L Coussens, T. Yang-Feng, Y. Liao, E Chen, A Gray, J McGrath, P. Seeburg, T. Libermann, J Schlessinger, U Francke, et al. (1985)
Science 230, 1132-1139
 |  Abstract »  |  PDF »

c-Cbl Is a Suppressor of the Neu Oncogene.

G. Levkowitz, S. Oved, L. N. Klapper, D. Harari, S. Lavi, M. Sela, and Y. Yarden (2000)
J. Biol. Chem. 275, 35532-35539
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products